Baker, Jillian - University of Nottingham

个人简介

After obtaining her medical degree and 4 years clinical experience, Jill Baker was awarded a Wellcome Trust Clinical Training Fellowship to undertake a PhD in molecular pharmacology in the Institute of Cell Signalling at the University of Nottingham (2001-2004). Jill then secured a Wellcome Trust Clinician Scientist Fellowship (2004-2009) to enable her to continue with her research on ß-adrenoceptors whilst continuing her specialist clinical training in respiratory medicine. Jill is currently the 2008 British Pharmacology Society's Bill Bowman travelling lecturer and is a previous winner of the British Thoracic Society's Young Investigator of the Year award (2003). She also serves on the Editorial Board of the British Journal of Pharmacology.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

BAKER JG and WILCOX RG, 2016. β-Blockers, heart disease and COPD: current controversies and uncertainties. Thorax. (In Press.) BAKER JG, PROUDMAN RGW and HILL SJ, 2015. Salmeterol's Extreme β2 Selectivity Is Due to Residues in Both Extracellular Loops and Transmembrane Domains. Molecular pharmacology. 87(1), 103-20 GHERBI, KAROLINA, MAY, LAUREN T., BAKER, JILLIAN G., BRIDDON, STEPHEN J. and HILL, STEPHEN J., 2015. Negative cooperativity across beta(1)-adrenoceptor homodimers provides insights into the nature of the secondary low-affinity CGP 12177 beta(1)-adrenoceptor binding conformation FASEB JOURNAL. 29(7), 2859-2871 SATO T, BAKER J, WARNE T, BROWN GA, LESLIE AG, CONGREVE M and TATE CG, 2015. Pharmacological Analysis and Structure Determination of 7-Methylcyanopindolol-Bound β1-Adrenergic Receptor. Molecular pharmacology. 88(6), 1024-34 BAKER JG, PROUDMAN RGW and HILL SJ, 2014. Identification of key residues in transmembrane 4 responsible for the secondary, low-affinity conformation of the human β1-adrenoceptor. Molecular pharmacology. 85(5), 811-29 MISTRY, S.N., BAKER, J.G., FISCHER, P.M., HILL, S.J., GARDINER, S.M. and KELLAM, B., 2013. Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists Journal of Medicinal Chemistry. 56(10), 3852-3865 BAKER JG, PROUDMAN RGW and HILL SJ, 2013. Impact of polymorphic variants on the molecular pharmacology of the two-agonist conformations of the human β1-adrenoceptor. PloS one. 8(11), e77582 WARNE, T., MOUKHAMETZIANOV, R., BAKER, J.G., NEHMé, R., EDWARDS, P.C., LESLIE, A.G.W., SCHERTLER, G.F.X. and TATE, C.G., 2011. The structural basis for agonist and partial agonist action on a β1-adrenergic receptor. Nature. 469(7329), 241-244 BAKER, J.G., ADAMS, L.A., SALCHOW, K., MISTRY, S.N., MIDDLETON, R.J., HILL, S.J. and KELLAM, B., 2011. Synthesis and characterization of high-affinity 4,4-difluoro-4-bora-3A,4A-diaza-s-indacene-labeled fluorescent ligands for human β-adrenoceptors Journal of Medicinal Chemistry. 54(19), 6874-6887 JILLIAN G BAKER, RICHARD GW PROUDMAN and CHRISTOPHER G TATE, 2011. The pharmacological effects of the thermostabilising (m23) mutations and intra and extracellular (β36) deletions essential for crystallisation of the turkey β-adrenoceptor NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 384, 71-91 BAKER, J.G., KEMP, P., MARCH, J., FRETWELL, L., HILL, S.J. and GARDINER, S.M., 2011. Predicting in vivo cardiovascular properties of β-blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses FASEB Journal. 25(12), 4486-4497 JILLIAN G BAKER, STEPHEN J HILL and ROGER J SUMMERS, 2011. Evolution of β-blockers - from anti-anginal drugs to ligand-directed signalling TRENDS IN PHARMACOLOGICAL SCIENCES. 32, 227-234 BAKER, J.G., MIDDLETON, R., ADAMS, L., MAY, L.T., BRIDDON, S.J., KELLAM, B. and HILL, S.J., 2010. Influence of fluorophore and linker composition on the pharmacology of fluorescent adenosine A1 receptor ligands British Journal of Pharmacology. 159(4), 772-786 BAKER, J.G., 2010. The selectivity of β-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors British Journal of Pharmacology. 160(5), 1048-1061 BAKER JG, 2010. A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors PLoS ONE. 5(11):, e15487. doi:10.1371/journal.pone.0015487 BAKER, J.G., PROUDMAN, R.G.W., HAWLEY, N.C., FISCHER, P.M. and HILL, S.J., 2008. Role of key transmembrane residues in agonist and antagonist actions at the two conformations of the human β1-adrenoceptor Molecular Pharmacology. 74(5), 1246-1260 BAKER, J G, 2008. A study of antagonist affinities for the human histamine H2 receptor. British Journal of Pharmacology. 153(5), 1011-21 WARNE, T., SERRANO-VEGA, M.J., BAKER, J.G., MOUKHAMETZIANOV, R., EDWARDS, P.C., HENDERSON, R., LESLIE, A.G.W., TATE, C.G. and SCHERTLER, G.F.X., 2008. Structure of a β1-adrenergic G-protein-coupled receptor Nature. 454(7203), 486-491 BAKER, JILLIAN G, 2008. Antagonist affinity measurements at the Gi-coupled human histamine H3 receptor expressed in CHO cells. BMC pharmacology. 8, 9 MIDDLETON,R, BRIDDON,S.J., CORDEAUX,Y., YATES,A.S., DALE,C.L., GEORGE,M., BAKER,J.G., HILL,S.J. and KELLAM,B., 2007. New Fluorescent Adenosine A(1)-Receptor Agonists That Allow Quantification of Ligand-Receptor Interactions in Microdomains of Single Living Cells. Journal of Medicinal Chemistry. 50(4), 782-793 BAKER, J.G. and HILL, S.J., 2007. A comparison of the antagonist affinities for the Gi and Gs-coupled states of the human adenosine A1 receptor Journal of Pharmacology and Experimental Therapeutics. 320(1), 218-228 BAKER, JILLIAN G and HILL, STEPHEN J, 2007. Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. Trends in Pharmacological Sciences. 28(8), 374-81 BAKER, J.G, 2005. Evidence for a secondary state of the human beta3-adrenoceptor. Molecular Pharmacology. 68(6), 1645-1655 BAKER, J.G, 2005. Site of action of beta-ligands at the human beta1-adrenoceptor. Journal of Pharmacology and Experimental Therapeutics. 313(3), 1163-1171 BAKER, J. G., 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors British Journal of Pharmacology. VOL 144(NUMB 3), 317-322